Arbutus Biopharma (ABUS) Earnings Date, Estimates & Call Transcripts $3.41 -0.04 (-1.16%) Closing price 04:00 PM EasternExtended Trading$3.40 -0.01 (-0.29%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Arbutus Biopharma Earnings Summary Arbutus Biopharma posted Q1 2025 earnings on May 14, 2025, reporting an EPS of -$0.13, which missed the consensus estimate of -$0.09 by $0.04. Quarterly revenue was reported to be $1.76 million, below analyst estimates of $2.54 million. With a trailing EPS of -$0.41, Arbutus Biopharma's earnings are expected to grow next year, from ($0.39) to ($0.34) per share. Upcoming Q2 Earnings DateJul. 30Before Market OpensEstimatedConsensus EPS (May. 14) -$0.09 Actual EPS (May. 14) -$0.13 Missed By -$0.04 Actual Revenue (May. 14) $1.76MQ1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)ABUS Upcoming EarningsArbutus Biopharma's next earnings date is estimated for Wednesday, July 30, 2025, based on past reporting schedules. Powered by Get Arbutus Biopharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataABUS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ABUS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Arbutus Biopharma Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ2 20251-$0.10-$0.10-$0.10Q4 20251-$0.11-$0.11-$0.11 Arbutus Biopharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 7/30/2025(Estimated)--------5/14/2025Q1 2025-$0.09-$0.13 -$0.04-$0.13$2.54M$1.76M3/27/2025Q4 2024-$0.08-$0.07+$0.01-$0.07$2.20M$1.57M8/1/2024Q2 2024-$0.10-$0.11 -$0.01-$0.11$1.54M$1.73M5/2/2024Q1 2024-$0.10-$0.10--$0.10$2.16M$1.53M2/29/2024Q4 2023-$0.12-$0.12--$0.12$4.74M$2.15M11/7/2023Q3 2023-$0.12-$0.12--$0.12$3.78M$4.66M8/3/2023Q2 2023-$0.12-$0.10+$0.02-$0.10$5.02M$4.65M Arbutus Biopharma Earnings - Frequently Asked Questions When is Arbutus Biopharma's earnings date? Arbutus Biopharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 30th, 2025 based off last year's report dates. Learn more on ABUS's earnings history. Did Arbutus Biopharma beat their earnings estimates last quarter? In the previous quarter, Arbutus Biopharma (NASDAQ:ABUS) missed the analysts' consensus estimate of ($0.09) by $0.04 with a reported earnings per share (EPS) of ($0.13). Learn more on analysts' earnings estimate vs. ABUS's actual earnings. How much revenue does Arbutus Biopharma generate each year? Arbutus Biopharma (NASDAQ:ABUS) has a recorded annual revenue of $6.40 million. How much profit does Arbutus Biopharma generate each year? Arbutus Biopharma (NASDAQ:ABUS) has a recorded net income of -$72.85 million. ABUS has generated -$0.41 earnings per share over the last four quarters. What is Arbutus Biopharma's EPS forecast for next year? Arbutus Biopharma's earnings are expected to grow from ($0.39) per share to ($0.34) per share in the next year. More Earnings Resources from MarketBeat Related Companies XENE Earnings Results AMRX Earnings Results OGN Earnings Results MIRM Earnings Results APLS Earnings Results ARWR Earnings Results VCEL Earnings Results NAMS Earnings Results BLTE Earnings Results HRMY Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again? This page (NASDAQ:ABUS) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
